融合-话题@MedSci - williamhill asia

#融合#

253篇内容 | 2634人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1525594, encodeId=fe7615255942f, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=国际络病学大会｜络病理论原创结合现代科技中西融合为微血管病防治打开突破口, objectType=article, longId=737756, objectId=451ce37756bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=451ce37756bc, replyNumber=0, likeNumber=62, createdTime=2022-09-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=451ce37756bc, moduleTitle=国际络病学大会｜络病理论原创结合现代科技中西融合为微血管病防治打开突破口, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=451ce37756bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525593, encodeId=5eb115255938b, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Genome Biology：伯晓晨/何松/张仲楠团队评估16种基于深度学习的癌症多组学数据融合算法, objectType=article, longId=737220, objectId=a9efe372209d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9efe372209d, replyNumber=0, likeNumber=88, createdTime=2022-08-30, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9efe372209d, moduleTitle=Genome Biology：伯晓晨/何松/张仲楠团队评估16种基于深度学习的癌症多组学数据融合算法, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a9efe372209d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525591, encodeId=94a31525591fb, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=积极推行“体医融合和非医疗健康干预”，《运动联合营养缓解2型糖尿病的专家共识》发布！, objectType=article, longId=735290, objectId=ef4ce35290ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef4ce35290ee, replyNumber=0, likeNumber=61, createdTime=2022-08-10, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef4ce35290ee, moduleTitle=积极推行“体医融合和非医疗健康干预”，《运动联合营养缓解2型糖尿病的专家共识》发布！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ef4ce35290ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525590, encodeId=275015255905f, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=BCR-ABL1融合基因阳性急性淋巴细胞白血病的那些小秘密, objectType=article, longId=732594, objectId=9881e3259437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9881e3259437, replyNumber=0, likeNumber=61, createdTime=2022-07-18, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9881e3259437, moduleTitle=BCR-ABL1融合基因阳性急性淋巴细胞白血病的那些小秘密, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9881e3259437)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525589, encodeId=ceb2152558934, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=真实世界研究与融合方法-真实世界研究中的自身对照研究如何设计，样本量如何计算？, objectType=article, longId=729708, objectId=b862e297083a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b862e297083a, replyNumber=0, likeNumber=54, createdTime=2022-06-18, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b862e297083a, moduleTitle=真实世界研究与融合方法-真实世界研究中的自身对照研究如何设计，样本量如何计算？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b862e297083a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525588, encodeId=ea2715255882c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=真实世界研究与融合方法-大样本多大才算大？单中心研究属不属于真实世界研究？, objectType=article, longId=729707, objectId=b51ae29707dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b51ae29707dd, replyNumber=0, likeNumber=66, createdTime=2022-06-18, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b51ae29707dd, moduleTitle=真实世界研究与融合方法-大样本多大才算大？单中心研究属不属于真实世界研究？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b51ae29707dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525592, encodeId=29d9152559276, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Nature子刊：科学家开发肿瘤融合基因预测新工具, objectType=article, longId=729578, objectId=ae57e29578cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae57e29578cc, replyNumber=0, likeNumber=67, createdTime=2022-06-16, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae57e29578cc, moduleTitle=Nature子刊：科学家开发肿瘤融合基因预测新工具, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ae57e29578cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525587, encodeId=3ea2152558e96, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=【即将直播】刘建平：真实世界研究与融合方法, objectType=article, longId=727430, objectId=e500e27430db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e500e27430db, replyNumber=0, likeNumber=51, createdTime=2022-05-22, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e500e27430db, moduleTitle=【即将直播】刘建平：真实世界研究与融合方法, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e500e27430db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525585, encodeId=20a11525585c6, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=新研究表明，采用堃博医疗Archimedes系统的融合透视和血管映射进行的虚拟支气管镜导航能安全有效地获得肺肿瘤高活检率, objectType=article, longId=301927, objectId=5a4c30192eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a4c30192eea, replyNumber=0, likeNumber=58, createdTime=2022-03-31, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a4c30192eea, moduleTitle=新研究表明，采用堃博医疗Archimedes系统的融合透视和血管映射进行的虚拟支气管镜导航能安全有效地获得肺肿瘤高活检率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5a4c30192eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525586, encodeId=da2a152558657, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=威廉亚洲博彩公司解读 | 马文斌教授：创新融合，未来可期——脑胶质瘤的未来研究方向, objectType=article, longId=301808, objectId=31843018089e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31843018089e, replyNumber=0, likeNumber=64, createdTime=2022-03-29, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31843018089e, moduleTitle=威廉亚洲博彩公司解读 | 马文斌教授：创新融合，未来可期——脑胶质瘤的未来研究方向, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=31843018089e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525584, encodeId=bf8c152558434, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=直播：脑认知与神经调控融合创新论坛-蓝手帕公益项目, objectType=article, longId=292590, objectId=2fe82925908b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fe82925908b, replyNumber=0, likeNumber=45, createdTime=2021-12-24, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fe82925908b, moduleTitle=直播：脑认知与神经调控融合创新论坛-蓝手帕公益项目, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2fe82925908b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525583, encodeId=77eb1525583cc, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=NEJM：肺癌靶向药成功挽救处于死亡边缘的ALK融合阳性高级别胶质瘤患儿, objectType=article, longId=292026, objectId=b5e3292026c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e3292026c4, replyNumber=0, likeNumber=76, createdTime=2021-12-18, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e3292026c4, moduleTitle=NEJM：肺癌靶向药成功挽救处于死亡边缘的ALK融合阳性高级别胶质瘤患儿, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b5e3292026c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525582, encodeId=a0821525582f2, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=【科室宣教】世界肺炎日——医防融合，守护呼吸，消除肺炎！, objectType=article, longId=220266, objectId=212c22026646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=212c22026646, replyNumber=0, likeNumber=58, createdTime=2021-11-14, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=212c22026646, moduleTitle=【科室宣教】世界肺炎日——医防融合，守护呼吸，消除肺炎！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=212c22026646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525581, encodeId=682c152558149, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=J Thorac Oncol: RNA深度测序显示融合异质性可预测克唑替尼对ALK重排非小细胞肺癌的治疗效果, objectType=article, longId=218427, objectId=9f9321842e08, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f9321842e08, replyNumber=0, likeNumber=79, createdTime=2021-10-13, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f9321842e08, moduleTitle=J Thorac Oncol: RNA深度测序显示融合异质性可预测克唑替尼对ALK重排非小细胞肺癌的治疗效果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9f9321842e08)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525580, encodeId=14dc15255800d, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=NEJM：肺癌靶向药成功挽救处于死亡边缘的ALK融合阳性高级别胶质瘤患儿, objectType=article, longId=216321, objectId=4e742163212c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e742163212c, replyNumber=0, likeNumber=78, createdTime=2021-08-27, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e742163212c, moduleTitle=NEJM：肺癌靶向药成功挽救处于死亡边缘的ALK融合阳性高级别胶质瘤患儿, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4e742163212c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525579, encodeId=1fcd15255e9a6, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=NEJM：单纯腰椎管减压vs器械融合减压治疗退行性腰椎滑脱, objectType=article, longId=215731, objectId=c741215e318f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c741215e318f, replyNumber=0, likeNumber=65, createdTime=2021-08-16, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c741215e318f, moduleTitle=NEJM：单纯腰椎管减压vs器械融合减压治疗退行性腰椎滑脱, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c741215e318f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525578, encodeId=fd8815255e8e5, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, objectType=article, longId=215464, objectId=286f215464c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286f215464c0, replyNumber=0, likeNumber=61, createdTime=2021-08-10, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286f215464c0, moduleTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=286f215464c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525577, encodeId=898215255e736, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), objectType=article, longId=215428, objectId=756f215428da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f215428da, replyNumber=0, likeNumber=62, createdTime=2021-08-09, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f215428da, moduleTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=756f215428da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525576, encodeId=3d2f15255e65f, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=君实生物完成全球抗PD-1/TGF-β双功能融合蛋白JS201临床试验首例患者给药, objectType=article, longId=215187, objectId=ada021518e57, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ada021518e57, replyNumber=0, likeNumber=57, createdTime=2021-08-04, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ada021518e57, moduleTitle=君实生物完成全球抗PD-1/TGF-β双功能融合蛋白JS201临床试验首例患者给药, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ada021518e57)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525575, encodeId=4e7215255e5b7, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）, objectType=article, longId=213322, objectId=b9b021332249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9b021332249, replyNumber=0, likeNumber=76, createdTime=2021-06-28, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9b021332249, moduleTitle=Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b9b021332249)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

融合

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#融合#

国际络病学大会｜络病理论原创结合现代科技中西融合为微血管病防治打开突破口

2022-09-05

licz0427 (审核中...)

前往app查看评论内容

#融合#

Genome Biology：伯晓晨/何松/张仲楠团队评估16种基于深度学习的癌症多组学数据融合算法

2022-08-30

licz0427 (审核中...)

前往app查看评论内容

#融合#

积极推行“体医融合和非医疗健康干预”，《运动联合营养缓解2型糖尿病的专家共识》发布！

2022-08-10

licz0427 (审核中...)

前往app查看评论内容

#融合#

BCR-ABL1融合基因阳性急性淋巴细胞白血病的那些小秘密

2022-07-18

licz0427 (审核中...)

前往app查看评论内容

#融合#

真实世界研究与融合方法-真实世界研究中的自身对照研究如何设计，样本量如何计算？

2022-06-18

licz0427 (审核中...)

前往app查看评论内容

#融合#

真实世界研究与融合方法-大样本多大才算大？单中心研究属不属于真实世界研究？

2022-06-18

licz0427 (审核中...)

前往app查看评论内容

#融合#

Nature子刊：科学家开发肿瘤融合基因预测新工具

2022-06-16

licz0427 (审核中...)

前往app查看评论内容

#融合#

【即将直播】刘建平：真实世界研究与融合方法

2022-05-22

licz0427 (审核中...)

前往app查看评论内容

#融合#

新研究表明，采用堃博医疗Archimedes系统的融合透视和血管映射进行的虚拟支气管镜导航能安全有效地获得肺肿瘤高活检率

2022-03-31

licz0427 (审核中...)

前往app查看评论内容

#融合#

威廉亚洲博彩公司解读 | 马文斌教授：创新融合，未来可期——脑胶质瘤的未来研究方向

2022-03-29

licz0427 (审核中...)

前往app查看评论内容

#融合#

直播：脑认知与神经调控融合创新论坛-蓝手帕公益项目

2021-12-24

licz0427 (审核中...)

前往app查看评论内容

#融合#

NEJM：肺癌靶向药成功挽救处于死亡边缘的ALK融合阳性高级别胶质瘤患儿

2021-12-18

licz0427 (审核中...)

前往app查看评论内容

#融合#

【科室宣教】世界肺炎日——医防融合，守护呼吸，消除肺炎！

2021-11-14

licz0427 (审核中...)

前往app查看评论内容

#融合#

J Thorac Oncol: RNA深度测序显示融合异质性可预测克唑替尼对ALK重排非小细胞肺癌的治疗效果

2021-10-13

licz0427 (审核中...)

前往app查看评论内容

#融合#

NEJM：肺癌靶向药成功挽救处于死亡边缘的ALK融合阳性高级别胶质瘤患儿

2021-08-27

licz0427 (审核中...)

前往app查看评论内容

#融合#

NEJM：单纯腰椎管减压vs器械融合减压治疗退行性腰椎滑脱

2021-08-16

licz0427 (审核中...)

前往app查看评论内容

#融合#

Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性

2021-08-10

licz0427 (审核中...)

前往app查看评论内容

#融合#

Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究)

2021-08-09

licz0427 (审核中...)

前往app查看评论内容

#融合#

君实生物完成全球抗PD-1/TGF-β双功能融合蛋白JS201临床试验首例患者给药

2021-08-04

licz0427 (审核中...)

前往app查看评论内容

#融合#

Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）

2021-06-28

科室
- - 订阅+
  - 更多科室
工具
服务